MannKind (MNKD)
(Real Time Quote from BATS)
$4.40 USD
+0.08 (1.85%)
Updated May 13, 2024 03:22 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum D VGM
Price, Consensus and EPS Surprise
MNKD 4.40 +0.08(1.85%)
Will MNKD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MNKD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MNKD
MannKind (MNKD) Upgraded to Strong Buy: Here's Why
Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
MNKD: What are Zacks experts saying now?
Zacks Private Portfolio Services
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
Other News for MNKD
MannKind Buy Rating Affirmed by Analyst Thomas Smith on Strong Revenue Growth and Promising Clinical Developments
Oppenheimer Remains a Buy on MannKind (MNKD)
MannKind Corp (MNKD) Q1 2024 Earnings Call Transcript Highlights: A Quarter of Robust Growth ...
Analysts Offer Insights on Healthcare Companies: LENZ Therapeutics (LENZ), MannKind (MNKD) and Aquestive Therapeutics (AQST)
MannKind: Q1 Earnings Snapshot